Non-Hodgkin Lenfoma Olgularının Geriye Dönük Değerlendirilmesi: Tek Merkez Deneyimi

Year 2023, , 60 - 67, 30.04.2023

Müzeyyen Aslaner Ak İlknur Çekim Şehmus Ertop

https://doi.org/10.52976/vansaglik.1167807

Abstract

AAmaç: Çalışmamızda Zonguldak Bülent Ecevit Üniversitesi Tıp Fakültesi Hematoloji Kliniğinde takip edilen 151 Non- Hodgkin lenfoma tanılı hastanın demografik verileri, tedavi yanıtları ile sağkalım analizlerinin yapılması amaçlandı.
Materyal ve Metod: Non- Hodgkin lenfoma tanısı ile izlenen 151 olgunun verileri geriye dönük olarak değerlendirildi.
Bulgular: Çalışmaya 151 hasta (81 kadın,70 erkek) dahil edildi. Ortanca yaş 62.6±12.9 olarak saptandı. Hastaların tanılarına bakıldığında 83(%55) hastanın diffüz büyük B hücreli lenfoma, 21(%13.9) hastanın marjinal zon lenfoma, 10(%6.6) hastanın foliküler lenfoma 26 (%17.2) hastanın mantle cell lenfoma, 9(%6.0) hastanın T hücreli lenfoma, 2(%1.3) hastanın diğer lenfoma tanısı aldığı görüldü. Hastaların 64’si tanesi ölmüş, 87 tanesi ise yaşıyor olarak saptandı. Tüm non-hodgkin lenfoma hastalarında ortalama sağ kalım süresi 64 ay iken hastalıksız sağ kalım süresi 63 ay saptandı.
Sonuç: Çalışmamızda 5 yıllık sağkalım oranı literatüre göre düşük saptandı. Bunun sebebi hasta popülasyonumuzun büyük çoğunluğunun 65 yaş üstü olması, ileri evre hastalık ve komorbidite oranının yüksek olmasına bağlı olduğunu düşünüyoruz.

Keywords

Non hodgkin lenfoma, Genel sağkalım, Hastalıksız sağkalım

Supporting Institution

yok

Project Number

yok

Retrospective Analysis of Non-Hodgkin Lymphoma Patients: A Single Institution Experience

Abstract

Objective: Demografic features, respond the treatment of 151 Non-Hodgkin lymphoma (NHL) patients observed at depertman of hematology,Zonguldak Bülent Ecevit University faculty of medicine in our study.
Material and Method: Data of 151 NHL patients were evaluated retrospectively.
Results: 151 patients (81 female, 70 male) were included in the study. The median age was 62.6±12.9 years. The diagnoses of the patients were as follows: 83(55%) patients had diffuse large B-cell lymphoma, 21 (13.9%) patients had marginal zone lymphoma, 10(6.6%) patients had follicular lymphoma, 26(17.2%) patients had mantle cell lymphoma, 9(6.0%) patients had T cell lymphoma, and the remaining 2(1.3%) patients had other types of lymphoma. 64 patients died, and 87 of them lived. The mean survival time for all NHL patients was 64 months, while the disease-free survival time was 63 months.
Conclusion: In our study, the 5-year survival rate was found to be lower than the literature. We think that this is due to the fact that the majority of our patient population is over 65 years old and the rate of advanced disease and comorbidity is high.

Keywords

Non-hodgkin lymphoma, Overall survival, Disease-free survival

Project Number

yok

References

• Anuar NA, Tey KWF, Ng SC, Teh AKH, Rahman MHFA, Chong BP et al. (2021). Outcomes of high dose therapy and autologous haematopoietic stem cell transplantation for non‐hodgkin lymphoma: A retrospective analysis in a resource‐limited country. Int J Clin Pract ,75(3), 13823.
• Armitage JO, Gascoyne RD, Lunning MA, Cavalli F (2017). Non-hodgkin lymphoma. Lancet, 390(10091), 298-310.
• Aslaner AK M, Sahip B. (2021). NonHodgkin lenfomalı hastalarda hepatit B prevalansının değerlendirilmesi ve profilaksinin yeri. LLM Dergi, 5(3), 57-60.
• Çetintepe T, Acar C, Solmaz Ş (2018). Non-Hodgkin Lenfoma Tanılı Hastalarımızın Retrospektif Değerlendirilmesi. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi, 22(3), 119-124.
• Leval L, Jaffe ES. (2020). Lymphoma classification. Cancer J, 26(3), 176-185.
• Howlader N, Morton LM, Feuer EJ, Besson C, Engels EA. (2016). Contributions of subtypes of non-Hodgkin lymphoma to mortality trends. Cancer Epidemiol Biomarkers Prev, 25(1),174-179.
• Isikdogan A, Ayyıldız O, Büyükçelik A, Arslan A, Tiftik N, Buyukbayram H et al. (2004). Non-Hodgkin’s lymphoma in southeast Turkey: clinicopathologic features of 490 cases. Ann Hematol., 83(5), 265-269.
• Issa DE, Schans SA, Chamuleau ME, Karim-Kos HE, Wondergem M, Huijgens PC et al. (2015). Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989–2010. Haematologica, 100(4), 525-533
• Kelling M, Sokol L, Dalia S.(2018). Hepatitis B reactivation in the treatment of non-Hodgkin lymphoma. Cancer Control, 25(1), 1073274818767879.
• Lee MY, Tan TD, Feng AC, Liu MC.(2006). Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven‐year experience in a single institution. Am J Hematol., 81(8), 568-575.
• Lugtenburg PJ, Lyon AR, Marks R, Luminari S (2019). Treatment of aggressive non-Hodgkin's lymphoma in frail patients: cardiac comorbidities and advanced age. Future Oncology, 15(11), 1197-205
• Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P et al. (2007). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109(5), 1857-61
• Siegel RL, Miller KD, Fuchs HE, Jemal A. (2022). Cancer statistics. CA Cancer J Clin., 72(1), 7– 33
• Smith A, Crouch S, Howell D, Burton C, Patmore R, Roman E. (2015). Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. Cancer Epidemiol., 39(6), 1103-1112.
• Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. (2021). Epidemiology of non-Hodgkin’s Lymphoma. Med Sci (Basel), 9(1), 5
• Tian C, Li Y, Liu S, Chen Z, Zhang Y, Yu Y et al. (2021). Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients. Sci Rep 11(1):4273
• Van Spronsen DJ, Janssen-Heijnen ML, LemmensVE, Peters WG, Coebergh JW. (2005). Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer. 41(7), 1051-1057.
• Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A , Mangone L et al (2007). Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol 8(9),784-796.
• Yılmaz Z, Çobanoğlu Ü (2020). Distribution of lymphoid neoplasms in Northeast Turkey: A retrospective analysis of 1136 cases according to the World Health Organization classification. Konuralp Medical Journal 12 (2), 208-215.